Fairvalue-Calculator Fairvalue-Calculator
EN DE

Editas Medicine, Inc (EDIT) Fair Value & Analysis

Healthcare · US · Market cap $413M

Price$2.76
Fair Value$0.8000
Upside-71.0%
Quality95/100
Evidence: Low Range $0.6000 – $1.00

Fair value as of: Jun 24, 2026

Analysis

Editas Medicine, Inc (EDIT) currently trades at $2.76, while our model-based Fair Value estimate is $0.8000 — implying the stock looks roughly 71.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Editas Medicine, Inc (EDIT) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $0.8000 versus a price of $2.76 — about −71% (overvalued). Model-based estimate, not financial advice.
What is the fair value of EDIT?
Our 21-model fair value for Editas Medicine, Inc is $0.8000 (as of Jun 24, 2026), built from audited fundamentals. The current price is $2.76.
What is the quality score of EDIT?
Editas Medicine, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.